Skip to Content
주식/증권 ➡️ 중립

Is This the Right Time to Retain ILMN Stock in Your Portfolio?

요약

Illumina advances its sequencing strategy with strong NovaSeq X momentum and clinical demand, but China's weakness and macro pressures cloud the outlook.